---
title: "Lifeon Pharmaceutical: Obtained the drug registration certificate for Timolol Maleate Eye Drops"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236937962.md"
description: "Lifeon Pharmaceutical announced that it has recently received the Drug Registration Certificate for Timolol Maleate Eye Drops issued by the National Medical Products Administration. This medication is used for ophthalmic intraocular pressure reduction and is suitable for treating intraocular hypertension and glaucoma. The Timolol Maleate Eye Drops for which the company has obtained the drug registration certificate are classified as Category 3 chemical drugs, with quality and efficacy consistent with the reference preparation. The production and sales of the drug may be affected by factors such as policies and market conditions, and there remains a certain degree of uncertainty"
datetime: "2025-04-22T10:05:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236937962.md)
  - [en](https://longbridge.com/en/news/236937962.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236937962.md)
generator: "portal-rs"
---

# Lifeon Pharmaceutical: Obtained the drug registration certificate for Timolol Maleate Eye Drops

Lifeon Pharmaceutical announced that it has recently received the Drug Registration Certificate for Timolol Maleate Eye Drops issued by the National Medical Products Administration. This medication is an ophthalmic agent used to lower intraocular pressure and is suitable for the treatment of ocular hypertension and glaucoma. The Timolol Maleate Eye Drops for which the company has obtained the drug registration certificate are classified as Category 3 chemical drugs, with quality and efficacy consistent with the reference preparation. The production and sales of the drug may be affected by factors such as policies and market conditions, and there remains a certain degree of uncertainty

### Related Stocks

- [003020.CN](https://longbridge.com/en/quote/003020.CN.md)

## Related News & Research

- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [Grace Therapeutics CEO presents at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/297910585.md)
- [Tetragon Financial Group Limited Announcement of Final Results of Tender Offer to Purchase Tetragon Non-Voting Shares](https://longbridge.com/en/news/298056608.md)
- [Xiaomi’s SU7 Ultra test car points to a more performance-focused model](https://longbridge.com/en/news/297995487.md)
- [Kyntra Bio CEO presents at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/297778123.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**